Asked by: Lee Dillon (Liberal Democrat - Newbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of repealing section 2(4) of the Law Reform (Personal Injuries) Act 1948.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The rising costs of clinical negligence claims against the National Health Service in England are of great concern to the Government. Costs have more than doubled in the last ten years and are forecast to continue rising, putting further pressure on NHS finances.
Although forecasts remain uncertain, it is likely that the costs of clinical negligence will continue to grow substantially. The Government Actuary’s Department forecasts that annual payments for compensation and legal costs will increase from £3 billion in 2024/25 to £4.1 billion by 2029/30.
As announced in the 10-Year Health Plan for England, David Lock KC is providing expert policy advice on the rising costs of clinical negligence and how we can improve patients’ experience of claims. The review is ongoing, following initial advice to ministers and the recent National Audit Office report.
We welcome the report by the National Audit Office. The results of David Lock’s work will inform future policy making in this area. No decisions on policy have been taken at this point, and the Government will provide an update on the work done and next steps in due course.
Asked by: Lee Dillon (Liberal Democrat - Newbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to address rising legal costs associated with clinical negligence claims.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The rising costs of clinical negligence claims against the National Health Service in England are of great concern to the Government. Costs have more than doubled in the last ten years and are forecast to continue rising, putting further pressure on NHS finances.
Although forecasts remain uncertain, it is likely that the costs of clinical negligence will continue to grow substantially. The Government Actuary’s Department forecasts that annual payments for compensation and legal costs will increase from £3 billion in 2024/25 to £4.1 billion by 2029/30.
As announced in the 10-Year Health Plan for England, David Lock KC is providing expert policy advice on the rising costs of clinical negligence and how we can improve patients’ experience of claims. The review is ongoing, following initial advice to ministers and the recent National Audit Office report.
We welcome the report by the National Audit Office. The results of David Lock’s work will inform future policy making in this area. No decisions on policy have been taken at this point, and the Government will provide an update on the work done and next steps in due course.
Asked by: Luke Murphy (Labour - Basingstoke)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure NHS Trusts comply with NICE CG143 and national sickle cell clinical standards in the management of acute sickle cell crises, particularly in relation to timely escalation of analgesia and adherence to individual care plans.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS England Sickle Cell and Thalassaemia Improvement Programme aims to address health inequalities through targeted interventions. A key priority for the programme has been supporting National Health Service trusts in the management of acute sickle cell crises.
The programme has rolled out seven sickle cell Emergency Department Bypass Accelerator Sites to provide rapid access to pain relief for uncomplicated vaso-occlusion crises. The sites across the country are mainly in areas with a high prevalence of sickle cell, with four based in London and three in the North of England. The accelerator sites operate a 24/7 service, providing patients with direct access to specialist sickle cell care, either through self-referral, ambulance pathways, or transfer between wards. An evaluation of the effectiveness of the units is being carried out by the National Institute for Health and Care Research with early indications suggesting significant improvements in time to analgesia as per the National Institute for Health and Care Excellence CG143 guideline. A full report is expected in Quarter four of 2026.
In 2024, NHS England funded a programme of work to ensure that all patients with sickle cell in London and Greater Manchester have access to a personalised digital care plan, with an ambition to expand to other regions when the technology becomes available.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of Northern Ireland being the only part of the UK unable to offer abiraterone routinely to eligible prostate cancer patients.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
There are no current plans to hold discussions with the Northern Irish Department of Health or the Health and Social Care Board on abiraterone access in Northern Ireland. Decisions on the availability of medicines in Northern Ireland are a matter for the Northern Ireland Executive.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has had discussions with the Northern Ireland (a) Department of Health and (b) Health and Social Care Board on levels of accessibility to abiraterone for non-metastatic prostate cancer across the UK.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
There are no current plans to hold discussions with the Northern Irish Department of Health or the Health and Social Care Board on abiraterone access in Northern Ireland. Decisions on the availability of medicines in Northern Ireland are a matter for the Northern Ireland Executive.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce risk of negligence in Accident and Emergency waiting rooms.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The rising costs of clinical negligence claims against the National Health Service in England are of great concern to the Government. Costs have more than doubled in the last 10 years and are forecast to continue rising, putting further pressure on NHS finances.
As announced in the 10-Year Health Plan for England, David Lock KC is providing expert policy advice on the rising costs of clinical negligence and how we can improve patients’ experience of claims. The review is ongoing, following initial advice to ministers and the recent National Audit Office report.
Over recent years, the NHS and the Department have taken significant steps forward to address the rising costs of clinical negligence and to improve patient safety, including by implementing significant programmes under the NHS Patient Safety Strategy, published 2019. The strategy is now achieving its aim of saving an extra 1,000 lives per year and £100 million in care costs per year.
In addition, the Government is committed to restoring urgent and emergency care waiting times to the standards set out in the NHS Constitution by the end of this Parliament, as laid out in out 10-Year Health Plan. The NHS Medium-Term Planning Framework sets out a clear trajectory to improve urgent and emergency care performance year-on-year, reducing long waits and improving patient experience.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps is he taking to help tackle the causes of negligence claims received by the NHS.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The rising costs of clinical negligence claims against the National Health Service in England are of great concern to the Government. Costs have more than doubled in the last 10 years and are forecast to continue rising, putting further pressure on NHS finances.
As announced in the 10-Year Health Plan for England, David Lock KC is providing expert policy advice on the rising costs of clinical negligence and how we can improve patients’ experience of claims. The review is ongoing, following initial advice to ministers and the recent National Audit Office report.
Over recent years, the NHS and the Department have taken significant steps forward to address the rising costs of clinical negligence and to improve patient safety, including by implementing significant programmes under the NHS Patient Safety Strategy, published 2019. The strategy is now achieving its aim of saving an extra 1,000 lives per year and £100 million in care costs per year.
In addition, the Government is committed to restoring urgent and emergency care waiting times to the standards set out in the NHS Constitution by the end of this Parliament, as laid out in out 10-Year Health Plan. The NHS Medium-Term Planning Framework sets out a clear trajectory to improve urgent and emergency care performance year-on-year, reducing long waits and improving patient experience.
Asked by: Mike Wood (Conservative - Kingswinford and South Staffordshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether any leadership and promotion schemes run by the Care Equality Commission are restricted to ethnic minorities and other protected characteristics.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has interpreted the question as referring to the Care Quality Commission (CQC), as there is no public body called the ‘Care Equality Commission’.
The CQC operates a positive action development programme aimed at addressing barriers to career progression, aligning with the ambitions set out in the Civil Service Diversity and Inclusion Strategy, to support colleagues from ethnic minority backgrounds and disabled colleagues.
Participation in the programme does not guarantee promotion, as all appointments are made through fair and open competition in accordance with the Civil Service Recruitment Principles.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of Northern Ireland being the only part of the UK without routine access to abiraterone for men with non-metastatic prostate cancer on patient outcomes across the UK.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
There are no current plans to hold discussions with the Northern Irish Department of Health or the Health and Social Care Board on abiraterone access in Northern Ireland. Decisions on the availability of medicines in Northern Ireland are a matter for the Northern Ireland Executive.
Asked by: Caroline Johnson (Conservative - Sleaford and North Hykeham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to inform families of his plans for (a) interim and (b) main payment compensation before the second anniversary of the publication of the Hughes Report.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is carefully considering the work by the Patient Safety Commissioner and her report, which set out options for redress for those harmed by valproate and pelvic mesh.
This is a complex issue involving input from different Government departments. Since taking up my post, I have met with the patient safety commissioner to discuss her recommendations and discussed how we may respond in the near term to recommendations regarding improving the outcomes and lives of people harmed by Valproate and Pelvic mesh. The Government will provide a further update to the Patient Safety Commissioner’s report.